Galmed Pharmaceuticals
Next Generation of Metabolic and Inflammatory Therapeutics
StartupGalmed Pharmaceuticals is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2000. Next Generation of Metabolic and Inflammatory Therapeutics. The company has raised a total of $150.3M across 5 funding rounds, currently at the Public stage. The company has 1-10 employees. Core technologies: Biologicals.
With $150.3M in total funding, Galmed Pharmaceuticals is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees1-10
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$7M
68 articles covered by sources including finance.yahoo.com,
www.prnewswire.com,
www.timesofisrael.com,
www.calcalistech.com,
www.biospace.com.
What does Galmed Pharmaceuticals do?
Galmed Pharmaceuticals is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. The company is also collaborating with the Hebrew University in the development of Amilo-5MER, a 5 amino acid synthetic peptide and recently initiated a first in human study.
How much funding has Galmed Pharmaceuticals raised?
Galmed Pharmaceuticals has raised $150.3M in total funding across 5 rounds. The company is currently at the Public stage.
What sector is Galmed Pharmaceuticals in?
Galmed Pharmaceuticals operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Biotechnology.
Where is Galmed Pharmaceuticals located?
Galmed Pharmaceuticals is based in 16 Tiomkin Street, Tel Aviv, Center District.